Endocrinology, Diabetes and Metabolism最新文献

{"title":"Comment on Pituitary Tumour Apoplexy as Cause of Death of Simonetta Vespucci.","authors":"Alexis Demas","doi":"10.1002/edm2.70334","DOIUrl":"10.1002/edm2.70334","url":null,"abstract":"","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"9 5","pages":"e70334"},"PeriodicalIF":2.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13535665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148876136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Letters to the Editor Regarding 'Role of Evogliptin for Intra-Class Therapeutic Interchange in Patients With Type 2 Diabetes Mellitus: Subgroup Analysis From a Multi-Center, Prospective, Observational Study (REVISE Study)'.","authors":"Jie-Eun Lee, Jun Hwa Hong, Min Soo Song, Jong Chul Won","doi":"10.1002/edm2.70300","DOIUrl":"10.1002/edm2.70300","url":null,"abstract":"","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"9 5","pages":"e70300"},"PeriodicalIF":2.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13521567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148841392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extended Use of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 1 Diabetes: 12-Month Extension of a Randomized Controlled Trial.","authors":"Eric Renard, Ruth S Weinstock, Alfred Penfornis, Jean-Pierre Riveline, Charles Thivolet, Trang T Ly","doi":"10.1002/edm2.70321","DOIUrl":"10.1002/edm2.70321","url":null,"abstract":"<p><strong>Background: </strong>The Omnipod 5 Automated Insulin Delivery (AID) System is safe and effective for individuals managing Type 1 diabetes (T1D). Longer-term studies may provide additional evidence of sustained effectiveness and safety of AID system use in T1D.</p><p><strong>Methods: </strong>This 12-month extension study was conducted following a multicenter randomized controlled trial (RCT) where participants used either AID (Omnipod 5) or standard therapy (current non-automated pump therapy) for 13 weeks. Participants in France (n = 76) could transition to or continue with AID for an additional 12 months. Glycemic, safety, and psychosocial outcomes during or at the end of the extension phase were compared with baseline or end of RCT, as appropriate.</p><p><strong>Results: </strong>Seventy-five participants enrolled in the extension phase. From RCT baseline to the end of the extension phase, time in range 70-180 mg/dL increased by 17.9% (p < 0.0001) or 4.3 h/day to 62.3%. Time above range > 180 mg/dL and mean sensor glucose decreased by 17.7% and 27.8 mg/dL (both p < 0.0001), respectively. HbA1c decreased from 8.33% to 7.18% (-1.14%; p < 0.0001). Glycemic improvements were maintained for those continuing with AID from the RCT intervention group and for those transitioning to AID from standard therapy. Diabetes Quality of Life-brief and Hypoglycemia Confidence Scale scores were maintained or improved at 6 and 12 months compared to RCT baseline. Adverse events were infrequent (12 per 100 person-years).</p><p><strong>Conclusions: </strong>Findings support the RCT results, demonstrating safety and sustained improvements in glycemic and psychosocial outcomes with the Omnipod 5 System in adults in France with T1D over 12 months.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov NCT05409131.</p>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"9 5","pages":"e70321"},"PeriodicalIF":2.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13528233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148866980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Cardiovascular Outcomes of GLP-1 Receptor Agonists Versus Bariatric Surgery: A Systematic Review and Network Meta-Analysis.","authors":"Erfan Shirmohammadi, Negar Ghasemloo, Navid Ebrahimi, Narjes Mohammadzadeh, Amir Ehtemami, Mahan Babaei, Shakiba Fardoost","doi":"10.1002/edm2.70311","DOIUrl":"https://doi.org/10.1002/edm2.70311","url":null,"abstract":"<p><strong>Background: </strong>Obesity, a major global health issue, heightens the risk of cardiovascular diseases, including major adverse cardiovascular events (MACE), heart failure (HF) and myocardial infarction (MI). This study provides the first network meta-analysis (NMA) integrating direct and indirect evidence to compare the cardiovascular efficacy of bariatric surgery (BS) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in individuals with obesity.</p><p><strong>Methods: </strong>A systematic review and NMA were performed in adherence to PRISMA guidelines. PubMed, Embase, Cochrane Library and Google Scholar were searched for studies published from January 2000 to September 2024. Eligible studies reported cardiovascular outcomes, specifically MACEs, HF and MI, in patients with obesity receiving BS, GLP-1RAs or control treatment. Fixed- and random-effects models were used to analyse hazard ratios (HRs) and risk ratios (RRs), with heterogeneity assessed with I² and consistency through node-splitting analysis.</p><p><strong>Results: </strong>Forty-three studies involving 932,380 patients were included BS was associated with significantly greater reductions in MACEs (HR 0.66; 95% CI 0.60-0.74), HF (HR 0.45; 95% CI 0.38-0.53) and MI (HR 0.53; 95% CI 0.45-0.63) compared with controls in random-effects models. GLP-1RAs reduced MACEs (HR 0.85; 95% CI 0.77-0.94) but showed non-significant effects on HF and MI. Despite high heterogeneity (I²: 66%-93%), directional consistency was observed across studies.</p><p><strong>Conclusions: </strong>BS demonstrated more consistent and statistically significant reductions in all cardiovascular outcomes compared to GLP-1RAs, which showed more variable efficacy, particularly for HF and MI. Nevertheless, GLP-1RAs remain effective evidence-based alternatives for cardiovascular risk reduction in patients who are not candidates for surgery, but future studies on newer GLP-1RAs are required. The high heterogeneity across studies highlights the need for cautious interpretation. These results may inform individualized treatment selection in patients with obesity at high cardiovascular risk.</p>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"9 5","pages":"e70311"},"PeriodicalIF":2.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148897931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Research Landscape on Leptin Resistance and Obesity-Related Metabolic Dysfunction: Trends, Networks and Visualisation Analysis (1995-2025).","authors":"Sa'ed H Zyoud","doi":"10.1002/edm2.70330","DOIUrl":"10.1002/edm2.70330","url":null,"abstract":"<p><strong>Background: </strong>Leptin resistance is closely linked to obesity, insulin resistance, inflammation and cardiometabolic disorders. However, the global research output on leptin resistance and obesity-related metabolic dysfunction has not been mapped in detail. This study aimed to analyse global research trends in this field from 1995 to 2025.</p><p><strong>Methods: </strong>Publications were retrieved from the Scopus database. Bibliometric indicators included annual growth, document type, productive countries, institutions, journals, highly cited publications and international collaboration. VOSviewer version 1.6.21 was used to visualise country collaboration and title-abstract term co-occurrence.</p><p><strong>Results: </strong>A total of 2162 publications were included. Publication output increased substantially across the study period but fluctuated, peaking in 2014 and remaining broadly stable thereafter. Articles were the most common document type (n = 1658; 76.69%), followed by reviews (n = 433; 20.03%). The United States ranked first (n = 741; 34.27%), followed by China (n = 255; 11.79%), Japan (n = 132; 6.11%), Spain (n = 131; 6.06%) and Germany (n = 124; 5.74%). Harvard Medical School was the most productive institution, and Endocrinology was the most active journal. Cowley et al. had the most cited publication, with 2052 citations. Term mapping revealed three main themes: 'clinical metabolic dysfunction and cardiometabolic risk,' 'hypothalamic leptin signalling and energy homeostasis,' and 'body weight regulation and developmental programming.'</p><p><strong>Conclusions: </strong>Research on leptin resistance and obesity-related metabolic dysfunction expanded substantially between 1995 and 2025, although annual output fluctuated and plateaued after its 2014 peak. The maps suggest a broadening of terminology from early leptin biology and experimental models towards inflammatory, cardiometabolic and mechanistic topics; this pattern should not be interpreted as proof of a causal or complete transition. Collaboration remained concentrated among high-output countries.</p>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"9 5","pages":"e70330"},"PeriodicalIF":2.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13521595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148841369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.","authors":"Chia Siang Kow, Kaeshaelya Thiruchelvam, Dinesh Sangarran Ramachandram, Abdullah Faiz Zaihan","doi":"10.1002/edm2.70325","DOIUrl":"10.1002/edm2.70325","url":null,"abstract":"<p><strong>Background: </strong>Semaglutide and tirzepatide produce substantial weight loss during treatment, but the trajectory of weight regain after discontinuation remains uncertain.</p><p><strong>Objective: </strong>To estimate post-discontinuation weight-regain trajectories and explore predictors of faster regain.</p><p><strong>Methods: </strong>We used published timepoint-level aggregate data from studies evaluating weight change after discontinuation of semaglutide or tirzepatide to perform a Bayesian hierarchical longitudinal re-analysis. The model estimated weight loss at cessation, monthly regain rate, time to 50% regain, and time to return to baseline weight. Bayesian meta-regression examined medication type, magnitude of initial weight loss, and post-discontinuation behavioural or lifestyle support. Longer-term estimates assumed a constant linear regain rate.</p><p><strong>Results: </strong>Six studies comprising 10 intervention arms and 1776 participants were included, with observed follow-up ranging from 4 to 52 weeks. Estimated weight loss at cessation was 15.35 kg (95% credible interval [CrI] 11.18-19.60), followed by regain of 1.04 kg/month (95% CrI 0.80-1.29). Based on the linear model, 50% of initial weight loss was projected to be regained by 7.50 months (95% CrI 5.05-10.57), with return to baseline weight by 15.00 months (95% CrI 10.10-21.13). Tirzepatide showed numerically faster regain than semaglutide in unadjusted analyses, but no clear independent drug-specific difference was evident after adjustment. Greater initial weight loss showed the strongest directional association with faster regain, although the credible interval included zero. Behavioural or lifestyle support was directionally associated with slower regain, but the estimate was imprecise.</p><p><strong>Conclusions: </strong>Weight regain after discontinuation of semaglutide or tirzepatide was rapid and clinically meaningful. Because estimates beyond 52 weeks were model-based extrapolations, they should be interpreted cautiously. Early monitoring and proactive maintenance planning may be warranted after treatment cessation.</p>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"9 5","pages":"e70325"},"PeriodicalIF":2.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13529306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148867033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasonography Cannot Exclude Osteomyelitis in Diabetic Foot Ulcers: A Cross-Sectional Diagnostic Accuracy Study Against Magnetic Resonance Imaging.","authors":"Maryam Haghighi-Morad, Hadi Vahedi, Arian Yousefi Fard, Behrooz Mohammadkhani Pordanjani, Seyyed Taher Seyyed Mahmoudi","doi":"10.1002/edm2.70320","DOIUrl":"https://doi.org/10.1002/edm2.70320","url":null,"abstract":"<p><strong>Background and aims: </strong>Diabetic foot ulcers (DFUs) can lead to amputation, especially when complicated by osteomyelitis (OM) or soft tissue infection. Although MRI is the standard imaging method, ultrasonography (US) is increasingly used because it is more accessible. This study compared the diagnostic performance of US and MRI in DFU-related infections.</p><p><strong>Methods: </strong>In this descriptive cross-sectional study, consecutive adults with diabetes and suspected diabetic foot infection underwent both US and MRI. One ulcer per patient wasanalysed. US was compared with expert clinical assessment for cellulitis and with MRI for abscess and OM, following IWGDF recommendations. Diagnostic measures were calculated overall and by ulcer severity.</p><p><strong>Results: </strong>Among 127 patients, most had advanced Wagner grades (3-5) and forefoot ulcers. Cellulitis was clinically present in all cases; MRI and US concordance with the clinical diagnosis was 100.0% and 99.2%, respectively. For abscesses, US showed 100% sensitivity but low specificity, resulting in moderate accuracy. For OM, US had very poor sensitivity (17.9%) despite high specificity, especially in severe ulcers. MRI detected no OM in moderate-grade ulcers.</p><p><strong>Conclusion: </strong>US showed near-complete concordance with MRI for cellulitis, though this was assessed in a study in which cellulitis was universally present, and US performs poorly for OM and cannot reliably exclude bone infection. It is best used as an initial triage tool, while MRI remains essential when OM is suspected. Because MRI is not a perfect reference standard, the findings reflect diagnostic concordance rather than absolute accuracy and support a tiered imaging approach.</p>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"9 5","pages":"e70320"},"PeriodicalIF":2.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148892317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Educational Programmes on Knowledge and Practice Related to Diabetic Foot Care Among Nurses: A Systematic Review.","authors":"Mohammad Al-Me'ani, Omar Alqaisi, Mohammed Dibas, Heyam Al-Aaraj, Yousef Rubbai","doi":"10.1002/edm2.70324","DOIUrl":"10.1002/edm2.70324","url":null,"abstract":"<p><strong>Background: </strong>Diabetes mellitus is a leading global non-communicable disease associated with significant morbidity, mortality and healthcare burden. Diabetic foot complications represent a leading cause of hospitalization and lower-limb amputation in this population.</p><p><strong>Objective: </strong>To systematically evaluate the effects of educational programmes on nurses' knowledge and practice regarding diabetic foot care.</p><p><strong>Methods: </strong>A systematic search of quasi-experimental studies from 2015 to 2024 was performed. Web of Science, Cochrane Library, CINAHL, MEDLINE and Scopus databases were searched using a comprehensive search strategy. The Joanna Briggs Institute Critical Appraisal Checklist for Quasi-Experimental Studies was used to evaluate methodological quality. The results were summarized narratively due to variations in study designs, interventions and outcome measures. The GRADE approach was used for assessment of the evidence certainty.</p><p><strong>Results: </strong>A total of nine studies met the inclusion criteria. Educational interventions were found to be consistently linked to enhanced knowledge and/or clinical practice concerning diabetic foot care among nurses in the included studies. Interactive and practical educational approaches appeared particularly promising; however, considerable heterogeneity existed in intervention content, duration, measurement instruments and follow-up periods. The overall certainty of evidence for both knowledge and practice outcomes was rated as very low.</p><p><strong>Conclusion: </strong>Educational programmes were consistently associated with improvements in nurses' knowledge and practice regarding diabetic foot care. The findings suggest that healthcare training could be integrated with ongoing professional development programmes, emphasizing experiential learning. However, the very low certainty of evidence and predominance of non-randomized quasi-experimental designs limit causal inference. More rigorous randomized or cluster-randomized studies with standardized outcome measures, longer follow-up and patient-level outcomes are needed.</p><p><strong>Trial registration: </strong>PROSPERO: CRD420261404535.</p>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"9 5","pages":"e70324"},"PeriodicalIF":2.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13521569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148841384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on 'Effects of Zinc Supplementation on Glycemic Control, Insulin Resistance, Inflammation and Oxidative Stress in Diabetes'.","authors":"Héctor Fuentes-Barría","doi":"10.1002/edm2.70328","DOIUrl":"10.1002/edm2.70328","url":null,"abstract":"","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"9 5","pages":"e70328"},"PeriodicalIF":2.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13529260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148867003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gonadotropin Suppression During Mini-Puberty as an Early Biomarker of Classic 21-Hydroxylase Deficiency.","authors":"Ryosei Iemura, Yuri Suzuki, Maki Gau, Ryuta Orimoto, Haruki Yamano, Hisae Nakatani, Shizuka Kirino, Yoko Saito, Eriko Adachi, Atsumi Tsuji-Hosokawa, Kenichi Kashimada, Kei Takasawa","doi":"10.1002/edm2.70317","DOIUrl":"10.1002/edm2.70317","url":null,"abstract":"<p><strong>Introduction: </strong>Newborn screening (NBS) for congenital adrenal hyperplasia caused by 21-hydroxylase deficiency (21OHD) relies on elevated 17-hydroxyprogesterone (17OHP) levels but is limited by a high false-positive rate and difficulty in distinguishing classic from non-classic forms. To evaluate whether the suppression of serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH) during mini-puberty can serve as an early biomarker of classic 21OHD.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of 37 infants evaluated for suspected 21OHD between 2013 and 2025. Subjects were classified as classic (C), non-classic (NC), or false-positive (FP) based on biochemical and genetic confirmation. Neonatal serum LH and FSH levels were compared among groups, and receiver operating characteristic (ROC) analyses were performed.</p><p><strong>Results: </strong>LH and FSH levels were significantly suppressed in classic 21OHD compared with NC and FP cases (p < 0.001). Gonadotropin concentrations demonstrated a stepwise pattern (C<NC<FP), although overlap limited the discrimination of non-classic disease. ROC analyses identified optimal cutoff values of 0.3 mIU/mL for LH (sensitivity 89.5%, specificity 83.3%) and 1.3 mIU/mL for FSH (sensitivity 94.7%, specificity 100%) for identifying classic 21OHD. Suppression was observed in both sexes and was particularly informative in male neonates.</p><p><strong>Conclusions: </strong>Suppressed LH and FSH levels during the neonatal period reflect the attenuation of mini-puberty and represent a characteristic endocrine feature of classic 21OHD. Gonadotropin measurement may provide a clinically accessible adjunct to NBS for the early identification of severe disease, particularly in male neonates and in the evaluation of 46,XX disorders/differences in sex development.</p>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"9 5","pages":"e70317"},"PeriodicalIF":2.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13535671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148876078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}